Effects of Akkermansia Muciniphila-Based Probiotics on Autonomic and Vascular Function in Humans
University of Minnesota
Summary
This randomized, double-blind, placebo-controlled pilot study will investigate the effects of an Akkermansia muciniphila-based probiotic supplement, Panthea Core, on autonomic and vascular function in postmenopausal women with hypertension. Up to 60 participants aged 45 to 65 years will be enrolled to obtain approximately 40 evaluable datasets. Participants will be randomly assigned to receive Panthea Core or a matched placebo capsule daily for 12 weeks. The study will evaluate safety, tolerability, menopausal symptoms, and changes in autonomic and vascular physiology. The primary mechanistic outcome is muscle sympathetic nerve activity (MSNA), measured using microneurography. Secondary physiological outcomes include heart rate variability, baroreflex sensitivity, endothelial function assessed by flow-mediated dilation, and blood pressure. Additional assessments will include sleep, menopausal symptoms, mood, cognitive function, circulating metabolic markers, and gut microbiome composition. Participants will complete baseline and post-intervention assessments, with additional safety monitoring throughout supplementation and approximately one month after the intervention.
Description
Akkermansia muciniphila is a bacterium normally found in the human gastrointestinal tract that has been associated with metabolic and immune regulation. Previous research suggests that changes in Akkermansia muciniphila abundance may be related to blood pressure regulation, autonomic nervous system function, and vascular health. However, the effects of direct supplementation on human autonomic and endothelial physiology have not been adequately characterized. This pilot study will evaluate the effects of a 12-week Akkermansia muciniphila-based probiotic supplement, Panthea Core, in postmenopa…
Eligibility
- Age range
- 45–65 years
- Sex
- Female
- Healthy volunteers
- No
Inclusion Criteria: * Female individuals, assigned female sex at birth, aged 45 to 65 years. * Clinician-diagnosed hypertension, either controlled or uncontrolled. * Postmenopausal status, defined as at least 12 months without menstruation or prior surgical removal of the ovaries. * Willing and able to provide informed consent. Exclusion Criteria: * Nicotine/tobacco, probiotic, or antibiotic use within the previous six months. * Body mass index of 40 kg/m² or greater. * Use of hormonal contraceptives or systemic exogenous hormones. * Diagnosis of diabetes. * Respiratory disease other than w…
Interventions
- Dietary SupplementPanthea Core
Panthea Core is an oral probiotic formulation containing live Akkermansia muciniphila (approximately 1 × 10\^8 active fluorescence units), pyridoxal-5'-phosphate (10 mg), spermidine trihydrochloride (1.2 mg), and 3,3'-diindolylmethane (100 mg). Participants will take the formulation once daily for 12 weeks. Study product will be distributed through the Investigational Drug Services Pharmacy.
- Dietary SupplementMatched Placebo
Participants will receive a matched oral placebo capsule administered once daily for 12 weeks. The placebo will be supplied by Panthea Inc. and dispensed through the Investigational Drug Services Pharmacy.
Location
- University of Minnesota - Children's Rehabilitation CenterMinneapolis, Minnesota